Valuation: Altimmune, Inc.

Market Cap 580M 507M 468M 430M 814M 55.84B 828M 5.59B 2.19B 27.27B 2.18B 2.13B 94.15B P/E 2026 *
-4.43x
P/E 2027 * -3.93x
Enterprise Value 196M 172M 159M 146M 276M 18.93B 281M 1.89B 744M 9.25B 738M 722M 31.92B EV / Sales 2026 *
47,927x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day-5.20%
1 week-9.29%
Current month-6.91%
1 month+8.02%
3 months-19.37%
6 months-33.25%
Current year-21.61%
1 week 2.81
Extreme 2.81
3.14
1 month 2.62
Extreme 2.62
3.4
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
01/05/26 Free

Director

48,800 0.0251%
01/05/26 Free

Director

48,800 0.0251%
01/05/26 Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-4.53%-9.29%-32.30%-11.01% 580M
-3.42%+10.05%+58.59%+87.70% 57.82B
-0.05%-6.20%+55.97%+124.61% 53.71B
-2.31%-9.39%+2.45%+417.67% 23.8B
-0.76%-2.15%-19.12%-15.14% 23.26B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-2.05%+34.41%-29.62% 17.81B
-4.55%-8.65%+194.32%+349.58% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
+0.18%-2.82%+23.83%+189.16% 13.96B
Average -1.98%+0.53%+40.83%+180.08% 24.49B
Weighted average by Cap. -1.70%+0.17%+48.52%+165.79%

Financials

2026 *2027 *
Net sales 4.1K 3.58K 3.31K 3.04K 5.76K 395K 5.86K 39.53K 15.53K 193K 15.4K 15.06K 666K -
Net income -112M -97.71M -90.36M -82.92M -157M -10.77B -160M -1.08B -423M -5.26B -420M -411M -18.16B -139M -122M -113M -103M -195M -13.41B -199M -1.34B -527M -6.55B -523M -511M -22.62B
Net Debt -383M -335M -310M -284M -538M -36.91B -547M -3.69B -1.45B -18.02B -1.44B -1.41B -62.23B -256M -224M -207M -190M -359M -24.67B -366M -2.47B -969M -12.04B -961M -940M -41.58B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
16/07/26 $2.835 -4.87% 2,073,670
15/07/26 $2.980 +1.71% 2,862,398
14/07/26 $2.930 -2.01% 3,298,979
13/07/26 $2.990 -1.97% 2,457,098
10/07/26 $3.050 -2.24% 2,992,854
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.980USD
Average target price
15.45USD
Spread / Average Target
+418.46%

Quarterly revenue - Rate of surprise